EMBL Ventures is an early stage life-science investor currently managing about € 26 million on behalf of major institutional and private investors. It is the primary venture vehicle of the European Molecular Biology Laboratory (EMBL) in Heidelberg/Germany.
Copyright © 2012 Affectis Pharmaceuticals AG. All Rights Reserved.
